Abstract
Immature erythroid cells have an exceptionally high capacity to synthesize haem that is, at least in part, the result of the unique control of iron metabolism in these cells. In erythroid cells the vast majority of Fe released from endosomes must cross both the outer and the inner mitochondria1 membranes to reach ferrochelatase, which inserts Fe into protoporphyrin IX. Based on the fact that Fe is specifically targeted into erythroid mitochondria, we have proposed that a transient mitochondria-endosome interaction is involved in Fe transfer to ferrochelatase [Ponka (1 997) Blood 89,l-251. In this study, we examined whether the inhibition of endosome mobility within erythroid cells would decrease the rate of 59Fe incorporation into haem. We found that, in reticulocytes, the myosin light-chain kinase inhibitor, wortmannin, and the calmodulin antagonist, W-7, caused significant inhibition of 59Fe incorporation from 59Fe-transferrin-labelled endosomes into haem. These results, together with
Introduction
Iron is an essential element in many metabolic processes and is indispensable for all organisms. It is a component of haem-containing proteins (such as haemoglobin, myoglobin and cytochromes) and innumerable non-haem-iron-containing proteins with vital functions in many metabolic processes. However, unless appropriately chelated, iron becomes insoluble and is potentially toxic. In vertebrates, iron is transported within the body between sites of absorption, storage and utilization by the plasma glycoprotein transferrin (Tf) [ l ] that binds iron very tightly but reversibly. Tf is recognized by specific cell-membrane Tf receptors (TfRs) that are crucial for cellular iron acquisition
[ 2 ] . T h e current view on iron acquisition via TfRmediated endocytosis is depicted schematically in Figure 1 (reviewed in [l] ). Until recently, the mechanism of iron transport across the endosomal membrane was elusive, but in 1997 two groups identified a compelling candidate for an endosoma1 iron transporter [3,4]. T h e transporter 
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Nramp2 {natural resistance-associated macrophage protein 2 ; also known as divalent-cation transporter 1 (DCT1) [4] or divalent-metal transporter 1 (DMTl)}, is encoded by a gene belonging to the Nramp family of genes identified by Gros et al. [S] . Since the substrate for Nramp2/DCT1/ D M T l is ferrous iron [4] , reduction of Fe(II1) must occur in endosomes; however, nothing is known about the mechanism of this process. Following its egress from endosomes, iron is then transported to intracellular sites of use and/or storage in ferritin, but this aspect of iron metabolism, including the nature of the elusive intermediary pool of iron and its cellular trafficking, remains enigmatic. Only in erythroid cells does some evidence exist for a specific targeting of iron toward mitochondria [6] where the enzyme which inserts ferrous ion into protoporphyrin IX, ferrochelatase, is localized (see below).
It is generally believed [7, 8] that, after crossing endosomal membranes, iron enters the 'labile intermediate pool' from which it is available for mitochondria1 haem synthesis, insertion into iron-dependent proteins and enzymes, and storage in ferritin. It has been proposed that iron in this pool may be complexed with citrate, sugars, some amino acids and nucleotides [7] , but the real chemical nature of this metabolically and kinetically active pool is ill-defined. T h e only abiding certainty is that this iron can be intercepted by strong chelators. However, this does not necessarily mean that the iron is complexed with low-molecular-mass ligands ; it may equally well be bound to as-yet-unidentified membraneassociated carriers.
Iron metabolism in erythroid cells is unique
Erythroid cells have by far the greatest need for iron, which is used for haemoglobin synthesis with remarkable efficiency and speed [6] . On a per-cell basis the rate of haem synthesis in the immature erythroid cells is at least an order of magnitude higher than in the liver, the second highest haem producer in the organism. Moreover, mature erythrocytes have negligible amounts of non-haem iron while they contain haem iron in remarkably high concentrations (20 mM). This indicates that the delivery of Tf-borne iron to haemoglobin occurs with extremely high efficiency. Indeed, after only a 3 min incubation of reticulocytes with 59Fe-Tf, about 80 O 0 of cell-associated 59Fe can be found in haem [9] . This can be explained, at least in part, by a specific targeting of iron towards mitochondria in haemoglobin-synthesizing cells. In erythroid cells, the vast majority of iron released from endosomes must cross both the outer and the inner mitochondrial membranes to reach ferrochelatase. Importantly, in haemoglobinsynthesizing cells, iron acquired from Tf continues to flow into mitochondria, even when the synthesis of protoporphyrin IX is markedly suppressed (e.g. by isonicotinic acid hydrazide or succinylacetone) [9-121. The chemical nature of the non-haem iron which accumulates in mitochondria is unknown, but it is possible that iron in excess may be stored in recently identified mitochondrial ferritin [ 1 31. A certain proportion of this iron accumulated in mitochondria is in a form readily available for haem synthesis when protoporphyrin IX formation is restored [9-111. Under these conditions, haem is quickly transported out of the mitochondria to combine with globin chains in the cytosol, suggesting that the majority of iron taken up by erythroid mitochondria can leave the organelle only after it is inserted into protoporphyrin IX. In contrast to erythroid cells, in non-erythroid cells iron in excess of metabolic needs ends up in cytosolic ferritin. T h e above observations strongly suggest that in erythroid cells some specific mechanisms and controls are involved in mitochondrial iron and haem metabolism.
Iron is targeted into reticulocyte mitochondria
Based on the facts that Tf-borne iron is extremely efficiently used for haemoglobin synthesis and that
Figure 2 A model for the terminal mitochondria-associated steps in the haem biosynthesis pathway
Three terminal enzymes, coproporphyrinogen 111 oxidase (CPO), protoporphyrinogen 111 oxidase (PPO) and ferrochelatase (FC), are associated with the inner mitochondrial membrane. Only ferrous iron (Fe2+) can be used by ferrochelatase, but neither the site where iron reduction occurs nor the source of electrons (e-) are known: it is tempting to speculate that only one reduction step, occumng in endosomes, is required for Fe2+ translocation from endosomes to ferrochelatase. Copro'gen, coproporphyrinogen Ill ; Proto'gen, protoporphyrinogen 111: 0. M., outer mitochondrial membrane; I. M., inner mitochondrial membrane. From [6] . Copyright American Society 
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virtually no cytoplasmic iron transport intermediate can be identified in reticulocytes, a new hypothesis of intracellular iron transport has been suggested [6] . This model proposes that after iron is released from Tf in the endosome, it is passed directly from endosomal protein to mitochondria1 protein and remains protein bound until it reaches ferrochelatase in the mitochondrion. Such a transfer of iron between proteins could be mediated by the direct interaction of the endosome with the mitochondrion (Figure 2) .
In this study we provided further evidence supporting this hypothesis. We specifically labelled reticulocyte endosomes with 59Fe bound to Tf and followed its incorporation into haem.
We found that the transfer of endosomal 59Fe into haem was very rapid (minutes) and required an unrestricted supply of protoporphyrin. Both ferrous (dipyridyl) and ferric [salicylaldehyde isonicotinoyl hydrazone (SIH)] iron chelators can intercept "Fe during its translocation from 59Fe-endosomes to protoporphyrin IX when reticulocytes are incubated at 37 "C. However, very little intracellular 59Fe can be acquired by the chelators when they are added during the lysis (4°C) of 59Fe-reticulocytes. In other words, at any given time during the transfer of 59Fe from endosomes towards ferrochelatase, the vast majority of 59Fe is bound to components that bind 59Fe with a stronger affinity than dipyridyl or S I H . Even more important, we found that the myosin light-chain kinase inhibitor, wortmannin, as well as the calmodulin antagonist, W-7, caused significant inhibition of j9Fe incorporation from 59Fe-Tflabelled endosomes into haem. Both agents are known to inhibit the microfilament motor, myosin, appearing to be involved in intracellular movement of endosomes. These results, together with confocal microscopy studies (using Tf and mitochondria labelled by distinct fluorescent markers), suggest that in erythroid cells a transient mitochondrion-endosome interaction may be involved in iron translocation to ferrochelatase (Figure 2) . As pointed out above, the substrate for the endosomal transporter Nramp2/DCT1 / D M T 1 is Fe2+, the redox form of iron which is also the substrate for ferrochelatase. These facts make the above hypothesis quite attractive, since ferrous ions would bypass an oxygen-rich cytosol in haemoglobin-synthesizing cells. Scott and Eaton [14] showed that trace amounts of 'free' iron in combination with cellular reducing equivalents oxidize haemoglobin. This report strongly suggests that a pool of free iron is capable of establishing a self-amplifying and self-propagating redox reaction with haemoglobin that can eventually lead to red cell destruction. Hence, the chaperone-like function of endosomes may be one of the mechanisms that keeps concentrations of reactive iron at extremely low levels. T h e intricate and highly organized structure of the intracellular matrix, together with the extremely rapid incorporation of iron into haemoglobin, argues against a freely diffusible and potentially toxic cytosolic iron pool, and suggests a more tightly coordinated and efficient mechanism.
